Display options
Cite
Briede I, Narbute I, Kumsars I, et al. Two-year clinical outcomes after implantation of an everolimus-eluting bioresorbable scaffold (Absorb) in stable angina and acute coronary syndrome patients. Single-centre real-life registry data. Postepy Kardiol Interwencyjnej. 2018;14(2):144-148doi: 10.5114/aic.2018.76405.
Briede, I., Narbute, I., Kumsars, I., Sondore, D., Trushinskis, K., Jegere, S., Latkovskis, G., Strenge, K., Rudzitis, A., & Erglis, A. (2018). Two-year clinical outcomes after implantation of an everolimus-eluting bioresorbable scaffold (Absorb) in stable angina and acute coronary syndrome patients. Single-centre real-life registry data. Postepy w kardiologii interwencyjnej = Advances in interventional cardiology, 14(2), 144-148. https://doi.org/10.5114/aic.2018.76405
Briede, Ieva, et al. "Two-year clinical outcomes after implantation of an everolimus-eluting bioresorbable scaffold (Absorb) in stable angina and acute coronary syndrome patients. Single-centre real-life registry data." Postepy w kardiologii interwencyjnej = Advances in interventional cardiology vol. 14,2 (2018): 144-148. doi: https://doi.org/10.5114/aic.2018.76405
Briede I, Narbute I, Kumsars I, Sondore D, Trushinskis K, Jegere S, Latkovskis G, Strenge K, Rudzitis A, Erglis A. Two-year clinical outcomes after implantation of an everolimus-eluting bioresorbable scaffold (Absorb) in stable angina and acute coronary syndrome patients. Single-centre real-life registry data. Postepy Kardiol Interwencyjnej. 2018;14(2):144-148. doi: 10.5114/aic.2018.76405. Epub 2018 Jun 19. PMID: 30008766; PMCID: PMC6041844.
Copy Download .nbib Format: NLM
Share it on

Postepy Kardiol Interwencyjnej. 2018;14(2):144-148. doi: 10.5114/aic.2018.76405. Epub 2018 Jun 19.

Two-year clinical outcomes after implantation of an everolimus-eluting bioresorbable scaffold (Absorb) in stable angina and acute coronary syndrome patients. Single-centre real-life registry data.

Postepy w kardiologii interwencyjnej = Advances in interventional cardiology

Ieva Briede, Inga Narbute, Indulis Kumsars, Dace Sondore, Karlis Trushinskis, Sanda Jegere, Gustavs Latkovskis, Karlis Strenge, Ainars Rudzitis, Andrejs Erglis

Affiliations

  1. Latvian Centre of Cardiology, Pauls Stradins Clinical University Hospital, University of Latvia, Riga, Latvia.
  2. Latvian Centre of Cardiology, Pauls Stradins Clinical University Hospital, Riga, Latvia.

PMID: 30008766 PMCID: PMC6041844 DOI: 10.5114/aic.2018.76405

Abstract

AIM: The aim of this long-term registry data was to evaluate 2-year clinical and angiographic outcomes after implantation of everolimus-eluting bioresorbable scaffolds (Absorb) from the Latvian Centre of Cardiology Real-life Registry.

MATERIAL AND METHODS: Between November 2012 and December 2014 in the Centre of Cardiology Real-life Bioresorbable Vascular Scaffold Registry, 187 patients with stable angina or acute coronary syndrome and available 2-year follow-up were selected. All patients had percutaneous coronary intervention (PCI) following bioresorbable scaffold (Absorb) implantation. At 2 years, clinical parameters were analysed in stable angina and acute coronary syndrome subgroups: all-cause death, cardiac death, non-cardiac death, myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), scaffold thrombosis (ST), cerebral infarction, in-scaffold restenosis and bleeding.

RESULTS: The clinical follow-up rate at 2 years was 96.2%. In-hospital death occurred in 2 (1.1%) patients, and 1 (0.5%) patient had in-hospital MI. At 2 years, the rate of all-cause death was 3.9% (

CONCLUSIONS: Bioresorbable scaffolds showed acceptable efficacy (target lesion revascularization) and safety (cardiac death, myocardial infarction, and scaffold thrombosis) results at mid-term follow-up in stable angina and acute coronary syndrome patients.

Keywords: bioresorbable vascular scaffold; percutaneous coronary intervention; scaffold thrombosis

Conflict of interest statement

One author has received consultancy fees, a research grant to the institution from Abbott Vascular, Boston Scientific, Biosensors, Cordis J&J, Medtronic. Other authors declare no conflict of interest.

References

  1. Postepy Kardiol Interwencyjnej. 2016;12(4):321-328 - PubMed
  2. Circulation. 1990 Oct;82(4):1193-202 - PubMed
  3. JACC Cardiovasc Interv. 2017 Apr 24;10(8):774-782 - PubMed
  4. EuroIntervention. 2018 Aug 03;14(5):e554-e561 - PubMed
  5. Circulation. 2007 May 1;115(17):2344-51 - PubMed
  6. Open Heart. 2014 Aug 21;1(1):e000064 - PubMed
  7. Lancet. 2016 Nov 19;388(10059):2479-2491 - PubMed
  8. Postepy Kardiol Interwencyjnej. 2016;12(2):108-15 - PubMed
  9. J Am Coll Cardiol. 2015 Jun 16;65(23):2496-507 - PubMed
  10. EuroIntervention. 2015 Feb;10(10):1144-53 - PubMed
  11. Circulation. 2011 Feb 22;123(7):779-97 - PubMed
  12. N Engl J Med. 2017 Jun 15;376(24):2319-2328 - PubMed
  13. JACC Cardiovasc Interv. 2016 Jun 27;9(12):1216-27 - PubMed
  14. Circulation. 2014 Jan 14;129(2):211-23 - PubMed

Publication Types